• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

    10/31/24 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTMX alert in real time by email

    SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report third quarter financial results on Thursday, November 7, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.

    Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. An archived replay of the webcast will be available on the Company's website.

    Audio Conference Call:

     U.S. Dial-in Number:  (800) 715-9871
        
     International Dial-in Number: (646) 307-1963
        
     Conference ID:  5171678
        

    About CytomX Therapeutics, Inc.

    CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX's vision is to create safer, more effective therapies for the treatment of cancer. CytomX's robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates ("ADCs"), T-cell engagers, and immune modulators such as cytokines. CytomX's clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule, EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CX-2051 was discovered in collaboration with Immunogen, now part of AbbVie. CX-801 is an interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

    Company Contact:

    Chris Ogden

    Chief Financial Officer

    [email protected]

    Investor Contact:

    Precision AQ (formerly Stern Investor Relations)

    Stephanie Ascher

    [email protected] 

    Media Contact:

    Redhouse Communications

    Teri Dahlman

    [email protected]



    Primary Logo

    Get the next $CTMX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • When will CytomX Therapeutics announce its third quarter financial results?

      CytomX Therapeutics, Inc. will report its third quarter financial results on November 7, 2024, after the U.S. market closes.

    • What time is the conference call for CytomX's financial results?

      The conference call to discuss the financial results will be held at 5:00 p.m. ET on November 7, 2024.

    • How can investors listen to the live conference call?

      Participants can access the live webcast from the Events and Presentations page on CytomX's website.

    • What is the focus of CytomX Therapeutics and what are some candidates in its pipeline?

      CytomX is focused on developing conditionally activated biologics for cancer treatment, with a pipeline that includes various therapeutic candidates like CX-904 and CX-2051.

    • Which companies has CytomX collaborated with for its cancer therapeutics?

      CytomX has established strategic collaborations with companies like Amgen, Astellas, and Bristol Myers Squibb to further its oncology-focused initiatives.

    Recent Analyst Ratings for
    $CTMX

    DatePrice TargetRatingAnalyst
    5/15/2025$5.00Neutral → Buy
    H.C. Wainwright
    4/14/2025$3.25 → $2.50Overweight
    Piper Sandler
    5/28/2024$2.25 → $3.50Neutral → Overweight
    Piper Sandler
    5/9/2024$8.00Neutral → Outperform
    Wedbush
    5/6/2024$2.50 → $8.00Hold → Buy
    Jefferies
    4/22/2024Underweight → Neutral
    JP Morgan
    11/14/2022$3.00 → $2.60Outperform → Market Perform
    BMO Capital Markets
    7/7/2022$16.00 → $4.00Buy → Neutral
    Mizuho
    More analyst ratings

    $CTMX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 2:35 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX's website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. About CytomX Therapeutics, Inc.CytomX is a clinical-stage, on

      5/29/25 8:00:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

      SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been dosed with CX-801 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in the ongoing Phase 1 dose escalation study (NCT06462794) evaluating safety and initial clinical activity in patients with metastatic melanoma. CX-801 is a dually masked interferon (IFN) alpha-2b PROBODY® cytokine. CX-801 has been intentionally designed by CytomX to harness the power of Interferon alpha-2b's immune stimulating properties in combination with checkpoint inhibition. In

      5/19/25 8:00:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

      SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an underwritten offering of 76,923,076 shares of its common stock at an offering price of $1.30 per share, before underwriting discounts and commissions. All of the shares are being offered by the Company. The gross proceeds from the offering are expected to be approximately $100 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on May 13, 2025, subject to customary closing conditions. The Company int

      5/12/25 6:50:52 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Mccarthy Sean A. sold $22,556 worth of shares (37,656 units at $0.60), decreasing direct ownership by 4% to 995,195 units (SEC Form 4)

      4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

      3/20/25 4:34:40 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Ogden Christopher sold $5,122 worth of shares (8,551 units at $0.60), decreasing direct ownership by 4% to 201,026 units (SEC Form 4)

      4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

      3/20/25 4:33:49 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Chu Yu-Waye sold $2,411 worth of shares (4,025 units at $0.60), decreasing direct ownership by 3% to 135,725 units (SEC Form 4)

      4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

      3/20/25 4:32:56 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    Leadership Updates

    Live Leadership Updates

    See more
    • CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

      SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors. "We are excited to welcome Zhen to our board," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "With his extensive experience and accomplishments in oncology, Zhen brings expertise that will help shape strategy across our multi-modality PROBODY® therapeutic pipeline as well as CytomX's continued growth an

      3/21/24 8:00:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (CMO). In this role, Dr. Chu will oversee clinical development of the Company's diversified portfolio of Probody® therapeutic candidates. "Wayne brings to CytomX substantial experience in clinical development strategy in the oncology space," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics. "His drug development experiences have contributed to multiple approvals and span therapeutic modalitie

      7/17/23 8:00:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

      SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company's next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022. Dr. Scarlett has served as a member of the CytomX Therapeutics board since June 2016, and is currently chair of the Compensation Committee and a member of the Audit Committee. He also serves as chairman and chief executive officer of Geron Corporation. "I would like to express my s

      4/14/22 4:15:00 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    Financials

    Live finance-specific insights

    See more
    • CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

      - Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) - - Initiated CX-2051 Phase 1 dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses. Additional CX-2051 Phase 1 data update expected by Q1 2026 - - Planning CX-2051 Phase 2 study initiation in 1H 2026 - - CX-801 (PROBODY® Interferon alpha-2b) Phase 1a translational data in advanced melanoma expected in 2H 2025 - - Company to host conference call today at 8 a.m. EST / 5 a.m. PST - SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics,

      5/12/25 6:15:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)

      - 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W) - - 3 of 7 evaluable patients (43%) with confirmed responses at upper expansion dose (10 mg/kg Q3W) - - Median progression free survival of 5.8 months as of April 7th 2025 data cutoff - - Encouraging initial safety profile with no dose limiting toxicities at data cutoff - - Planning Phase 2 study initiation in 1H 2026 - - Conference call on Monday, May 12 at 8:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, to

      5/12/25 6:15:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

      SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Monday, May 12, 2025, before the open of the U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to j

      5/5/25 8:00:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

      SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

      11/14/24 4:26:32 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

      SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

      11/14/24 4:00:06 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

      SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

      11/14/24 3:03:21 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CytomX Therapeutics upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded CytomX Therapeutics from Neutral to Buy and set a new price target of $5.00

      5/15/25 8:05:24 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on CytomX Therapeutics with a new price target

      Piper Sandler resumed coverage of CytomX Therapeutics with a rating of Overweight and set a new price target of $2.50 from $3.25 previously

      4/14/25 8:16:21 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $3.50 from $2.25 previously

      5/28/24 7:31:35 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    SEC Filings

    See more
    • SEC Form 8-K filed by CytomX Therapeutics Inc.

      8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)

      5/28/25 4:06:12 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.

      SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

      5/15/25 4:15:24 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by CytomX Therapeutics Inc.

      8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)

      5/13/25 4:05:20 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care